首页|Targeting the adenosine A2A receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson's disease

Targeting the adenosine A2A receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson's disease

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Adenosine exerts its dual functions of homeostasis and neuromodulation in the brain by acting at mainly 2 G-protein coupled receptors,called A1 and A2A receptors.The adenosine A2A receptor(A2AR)antago-nists have been clinically pursued for the last 2 decades,leading to final approval of the istradefylline,an A2AR antagonist,for the treatment of OFF-Parkinson's disease(PD)patients.The approval paves the way to develop novel therapeutic methods for A2AR antagonists to address 2 major unmet medical needs in PD and traumatic brain injury(TBI),namely neuroprotection or improving cognition.In this review,we first consider the evidence for aberrantly increased adenosine signaling in PD and TBI and the sufficiency of the increased A2AR signaling to trigger neurotoxicity and cognitive impairment.We further discuss the increasing preclinical data on the reversal of cognitive deficits in PD and TBI by A2AR antagonists through control of degenerative proteins and synaptotoxicity,and on protection against TBI and PD pathologies by A2AR antagonists through control of neuroinflammation.Moreover,we provide the supporting evi-dence from multiple human prospective epidemiological studies which revealed an inverse relation between the consumption of caffeine and the risk of developing PD and cognitive decline in aging population and Alzheimer's disease patients.Collectively,the convergence of clinical,epidemiological and experimental evidence supports the validity of A2AR as a new therapeutic target and facilitates the design of A2AR antagonists in clinical trials for disease-modifying and cognitive benefit in PD and TBI patients.

Receptor,Adenosine A2AAdenosine A2 receptor antagonistsParkinson's diseaseBrain injuries,traumatic

Yan Zhao、Yuan-Guo Zhou、Jiang-Fan Chen

展开 >

Department of Army Occupational Disease,State Key Laboratory of Trauma,Burns and Combined Injury,Research Institute of Surgery,Daping Hospital,Army Medical University,Chongqing,400042,China

The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center,The State Key Laboratory of Ophthalmology,Optometry and Vision Science,Wenzhou Medical University,Wenzhou,325035,Zhejiang Province,China

Oujiang Laboratory(Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),Wenzhou,325035,Zhejiang Province,China

国家自然科学基金国家自然科学基金国家自然科学基金Startup Funds from the Oujiang Laboratory(the Zhejiang Provincial Key Laboratory for Regenerative Medicine and Eye-Brain Dis

817711768215071055882151308OJQDSP2022007

2024

10.1016/j.cjtee.2023.08.003

中华创伤杂志(英文版)
中华医学会

中华创伤杂志(英文版)

CSTPCD
影响因子：0.608
ISSN：1008-1275
年,卷(期)：2024.27(3)
  • 163